Potentials for the additional medical correction cytoprotectors in patients with chronic heart fa and nonalcoholic fatty liver disease


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The prospective randomized open-label 16-week trials studied 2-ethyl-6-methyl-3-hydroxypyridine succinat and trimetazidine succinate (part of complex treatment) effects in patients with chronic heart failure and type 2 diabetes mellitus, on structural and functional parameters of the сог and liver. Including of 2-ethyl-6-methyl-3-hydroxypyridine succinat and trimetazidine succinate in basis therapy of chronic heart failure and diabetes mellitus type 2 statistically significant increase ejection fraction of left ventricle, reduce triglycerids, decrease the level of fasting glucose, glycated hemoglobin and insulin resistance. Hepatoprotecive facilities of 2-ethyl-6-methyl-3-hydroxypyridine succinat were demonstrated.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Mikhail Statsenko

Volgograd state medical university

Email: mestatsenko@rambler.ru
MD, professor, head of the Department of internal medicine of pediatric and dental faculties

Svetlana Turkina

Volgograd state medical university

Email: turkinasv@rambler.ru
MD, professor of the Department of internal medicine of pediatric and dental faculties

Nataliya Shilina

Volgograd state medical university

PhD, assistant of the Department of internal medicine of pediatric and dental faculties

Marina Kosivtsova

Volgograd state medical university

Email: marinalekcandrovna@yandex.ru
assistant of the Department of internal medicine of pediatric and dental faculties

Әдебиет тізімі

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur. Heart J. 2016;37:2129-200.
  2. Mantovani A., Pernigo M., Bergamini C., Bonapace S., Lipari P., Pichiri I. nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS ONE. 2015;10(8):e0135329.
  3. Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015;62:47-64.
  4. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010;363:1341-50.
  5. VanWagner L.B., Wilcox J.E., Colangelo L.A. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62:773-83.
  6. Targher G., Mantovani A., Pichiri I. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin. Sci. 2013;125:301-9.
  7. Valbusa F., Bonapace S., Grillo C., Scala L., Chiampan A., Rossi A., Zoppini G., Lonardo A., Arcaro G., Byrne C.D., Targher G. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine (Baltimore). 2016;95(7):e2760.
  8. Dhingra R., Gona P., Wang T.J., Fox C.S., D'Agostino R.B. Sr, Vasan R.S. Serum gamma-glutamyltransferase and risk of heart failure in the community. Arterioscler. Thromb. Vasc. Biol. 2010;30:1855-60.
  9. Wannamethee S.G., Whincup P.H., Shaper A.G. Gamma-glutamyl-transferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler. Thromb. Vasc. Biol. 2012;32:830-5.
  10. Wang Y., Tuomilehto J., Jousilahti P. Serum Y-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99:163-67.
  11. Bugianesi E. Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: another piece of the puzzle. Hepatology. 2008;47(1):2-4.
  12. Abel E.D., O'Shea K.M., Ramasamy R. Insulinresistance: metabolic mechanisms and consequences in the heart. Arterioscl.Tromb. Vasc. Biol. 2012;32(9):2068-76.
  13. Boden G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 2011;18(2):139-43.
  14. Rijzewijk L.J., Jonker J.T., van der Meer R.W. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am. Coll. Cardiol. 2010;56(3);225-33.
  15. Perseghin G., Lattuada G., De Cobelli F. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47(1):51-8.
  16. Стаценко М.Е., Туркина С.В., Лемперт Б.А., Евтерева Е.Д. Использование метаболических средств в комплексной терапии ишемической болезни сердца. Лечащий врач. 2012;3:77-82. [Statsenko M.Ye., Turkina S.V., Lempert B.A., Yevterev Ye.D. Use of metabolic agents into the combined therapy of ischemic heart disease. Lechashchy vrach. 2012;3:77-82 (in Russ.)]
  17. Михин В.П. Кардиоцитопротекторы - новое направление клинической кардиологии. Архивь внутренней медицины. 2011;1:21-8. [Mikhin V.P. Cardiocytoprotectors is a new area of clinical cardiology. Archive of internal medicine. 2011;1:21-8 (in Russ.)]
  18. Spaniol M., Kaufmann P., Beier K., Wüthrich J., Török M., Scharnagl H., März W., Krähenbühl S. Mechanisms of liver steatosis in rats with systemiccarnitine deficiency due to treatment with trimethylhydraziniumpropionate. J. Lipid Res. 2003;44:144-53.
  19. Yilmaz E. The diagnostic role of ultrasonograhyy in liver streatosis. Turk. J. Gastroenterol. 1999;2:96-100.
  20. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
  21. Angulo P. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
  22. Matthews D.R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
  23. Федулаев Ю.Н., Павлюченко Н.С., Пинчук Т.В., Галачиева С.Х., Козина А.А., Рыженков В.Н. Влияние триметазидина на показатели трансмитрального кровотока у больных с диастолической сердечной недостаточностью. Рациональная фармакотерапия в кардиологии. 2013;9(4):386-9. [Fedulaev Yu.N., Pavlyuchenko N.S., Pinchuk T.V., Galachieva S.Kh., Kozina A.A., Ryzhenkov V.N. The effect of trimetazidine on indicators of transmitral blood flow in patients with diastolic heart failure. Rational pharmacotherapy in cardiology. 2013;9(4):386-9 (in Russ.)]
  24. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1 121-40.
  25. Turgut O., Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J. Atheroscler. Thromb. 2011;18(3):177-81.
  26. Di Napoli P., Taccardi A.A., Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91(2):161-5.
  27. Илюхин О.В., Тарасов Д.Л., Пром А.К., Калганова Е.Л., Термисултанова Т.Х., Илюхина М.В. Сравнительная оценка эластических свойств магистральных артерий у больных стабильной стенокардией на фоне метаболической терапии. Российский кардиологический журнал. 2012;1(93):24-30. [Ilyukhina O.V., Tarasov D.L., Prom A.K., Kalganova Ye.L., Termisultanova T.Kh., Ilyukhin M.V. Comparative evaluation of elastic properties of major arteries in patients with stable angina on a background of metabolic therapy. Russ, Cardiol. J. 2012;1(93):24-30 (in Russ.)]
  28. Инжутова А.И., Быкова В.В., Новикова Т.В., Орлова Т.П., Ларионов А.А., Лопатина О.Л., Михуткина С.В., Петрова М.М., Салмина А.Б. Улучшение функции эндотелия цитопротектором триметазидин при эссенциальной и ятрогенной артериальной гипертензии, вызванной сунитинибом. Вестник науки Сибири. 2012;4(3):291-306. [Inzhutova A.I., Bykov V.V., Novikova T.V., Orlova T.P., Larionov A.A., Lopatina O.L., Mikhutkina S.V., Petrova M.M., Salmina A.B. Improvement in endothelial function with cytoprotector trimetazidine in essential and iatrogenic arterial hypertension induced by sunitinib. J. Sci. of Siberia. 2012;4(3):291-306 (in Russ.)]

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>